Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar

Area of Science:

• Cardiovascular Pharmacology
• Nutraceutical Science
• Metabolic Health

Background:

• Red yeast rice (RYR) extracts are recognized as potent cholesterol-lowering nutraceuticals.
• Monacolin K, the active compound in RYR, functions as a reversible inhibitor of HMG-CoA reductase.
• Hypercholesterolemia management is crucial for cardiovascular disease prevention.

Purpose of the Study:

• To evaluate the efficacy and safety of red yeast rice (RYR) for cholesterol reduction.
• To assess the impact of RYR on lipid profiles and cardiovascular risk markers.
• To determine RYR's potential role in managing hypercholesterolemia, especially in statin-intolerant individuals.

Main Methods:

• Review of clinical trials and studies on red yeast rice (RYR) efficacy.
• Analysis of monacolin K's mechanism of action as an HMG-CoA reductase inhibitor.
• Assessment of reported effects on lipid levels, endothelial function, and cardiovascular events.

Main Results:

• Daily consumption of RYR (containing monacolin K) reduces low-density lipoprotein (LDL)-cholesterol by 15-25% within 6-8 weeks.
• RYR intake is associated with decreased total cholesterol, non-HDL cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein.
• Potential improvements in endothelial function, arterial stiffness, and cardiovascular event prevention have been observed, with minimal risk of mild myalgia.

Conclusions:

• RYR is an effective nutraceutical for managing mild to moderate hypercholesterolemia.
• It serves as a viable therapeutic option for patients unable to tolerate statins or other cholesterol-lowering therapies.
• RYR can support lifestyle modifications for cardiovascular health management.